HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2020-11-06Clinical Trial Update: Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients [Phase 3]
A Phase 3 pharmacokinetics study of a maraviroc and boosted atazanavir dual regimen in stable HIV-infected patients was withdrawn.
-
CLINICAL_TRIALS trial_result · 2020-11-06Clinical Trial Update: Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) [Phase 4]
Phase 4 trial update on using less neurotoxic drugs in patients with HIV-associated neurocognitive disorder (HAND), currently terminated.
-
CLINICAL_TRIALS trial_result · 2020-11-04Clinical Trial Update: Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention [Phase 1, Phase 2]
An update on Phase 1/2 trials assessing safety, tolerability, and immunogenicity of HIV prevention vaccines using Ad26 mosaic vectors (homol…
-
CLINICAL_TRIALS trial_result · 2020-11-04Clinical Trial Update: ATN 151 Work-to-Prevent: Employment as HIV Prevention [NA]
Completed clinical trial (NCT03313310) investigating work-to-prevent employment as a method of HIV prevention; results posted in 2020.
-
FDA label_change · 2020-10-30FDA Approved: SELZENTRY — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for SELZENTRY (maraviroc) submitted by ViiV Healthcare. The approval results in changes to the l…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-10-30FDA Approved: SELZENTRY — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for SELZENTRY (maraviroc) from ViiV Healthcare Company, resulting in an update to the drug's lab…
-
CLINICAL_TRIALS trial_result · 2020-10-27Clinical Trial Update: INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV [NA]
A terminated clinical trial evaluating varying intervals of antiretroviral therapy to improve outcomes in HIV-1 infection.
-
FDA approval · 2020-10-21FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for KALETRA (lopinavir/ritonavir) submitted by AbbVie Inc.
-
FDA approval · 2020-10-21FDA Approved: NORVIR — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for NORVIR (ritonavir) from AbbVie Inc.
-
FDA approval · 2020-10-21FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for KALETRA (lopinavir/ritonavir) submitted by AbbVie, updating the status of this antiretroviral th…
-
FDA approval · 2020-10-21FDA Approved: NORVIR — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Norvir (ritonavir) from AbbVie.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: A Safety and Immune Response Study of 2 Experimental HIV Vaccines [Phase 1, Phase 2]
Phase 1/2 clinical trial update describing safety and immune response of two experimental HIV vaccines; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 [Phase 4]
Phase 4 trial evaluating systematic empirical versus test-guided anti-tuberculosis treatment in severely immunosuppressed HIV patients start…
-
CLINICAL_TRIALS research · 2020-10-19Clinical Trial Update: Sustainable HIV Risk Reduction Strategies for Probationers [NA]
A completed clinical trial study on sustainable HIV risk reduction strategies for probationers; results posted in 2020.
-
EMA approval · 2020-10-16First long-acting injectable antiretroviral therapy for HIV recommended for approval
The EMA recommends approval of the first long-acting injectable antiretroviral therapy for HIV, representing a new treatment option with les…
-
CLINICAL_TRIALS trial_result · 2020-10-08Clinical Trial Update: Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants [Phase 1]
Phase 1 study evaluating safety, pharmacokinetics, and antiviral activity of Bictegravir (GS-9883) in HIV-1 infected participants has comple…
-
CLINICAL_TRIALS trial_result · 2020-09-28Clinical Trial Update: A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002) [Phase 1]
Phase 1 trial of MK-8527 in HIV-1 infected participants has completed; results posted.
-
FDA approval · 2020-09-24FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for REYATAZ (atazanavir), indicating a modification to the approved labeling. The submission was fil…
-
FDA approval · 2020-09-24FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for Reyataz (atazanavir) submitted by E.R. Squibb & Sons, L.L.C.
-
CLINICAL_TRIALS trial_result · 2020-09-22Clinical Trial Update: IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV [NA]
Trial update for IMPAACT 2002 evaluating cognitive behavioral therapy plus medication management for depression in youth with HIV; study com…
-
CLINICAL_TRIALS trial_result · 2020-09-21Clinical Trial Update: Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals [Phase 4]
Phase 4 clinical trial update evaluating a package of care to improve retention in ART and reduce mortality among treatment-naive HIV-infect…
-
CLINICAL_TRIALS trial_result · 2020-09-21Clinical Trial Update: mHealth for ART Adherence by HIV+ African Americans [Phase 2]
Phase 2 clinical trial evaluating a mobile health intervention to improve ART adherence in HIV-1-infected African Americans; study completed…
-
CLINICAL_TRIALS trial_result · 2020-08-31Clinical Trial Update: A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects [Phase 2]
Phase IIb study evaluating a long-acting intramuscular regimen of cabotegravir for maintenance of virologic suppression in HIV-1 infected AR…
-
CLINICAL_TRIALS trial_result · 2020-08-28Clinical Trial Update: Does Rosuvastatin Delay Progression of Atherosclerosis in HIV [Phase 4]
Phase 4 trial updating whether rosuvastatin delays progression of atherosclerosis in people with HIV; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-08-27Clinical Trial Update: Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants [Phase 3]
Phase 3 trial evaluating switching virologically suppressed HIV-1 patients to a fixed-dose combination of bictegravir/emtricitabine/tenofovi…